ZA989745B - Peptides capable of inhibiting the interaction between the presenilines and the precursor of the beta-amyloid peptide and/or teh beta-amyloid peptide and interaction test for research of mulecules inhibiting the said interaction - Google Patents

Peptides capable of inhibiting the interaction between the presenilines and the precursor of the beta-amyloid peptide and/or teh beta-amyloid peptide and interaction test for research of mulecules inhibiting the said interaction

Info

Publication number
ZA989745B
ZA989745B ZA989745A ZA989745A ZA989745B ZA 989745 B ZA989745 B ZA 989745B ZA 989745 A ZA989745 A ZA 989745A ZA 989745 A ZA989745 A ZA 989745A ZA 989745 B ZA989745 B ZA 989745B
Authority
ZA
South Africa
Prior art keywords
beta
interaction
app
inhibiting
amyloid peptide
Prior art date
Application number
ZA989745A
Other languages
English (en)
Inventor
Christian Czech
Luc Mercken
Laurent Pradier
Soline Reboul-Becquart
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of ZA989745B publication Critical patent/ZA989745B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
ZA989745A 1997-10-24 1998-10-26 Peptides capable of inhibiting the interaction between the presenilines and the precursor of the beta-amyloid peptide and/or teh beta-amyloid peptide and interaction test for research of mulecules inhibiting the said interaction ZA989745B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9713384A FR2770217B1 (fr) 1997-10-24 1997-10-24 Peptides capables d'inhiber l'interaction entre les presenilines et le precurseur du peptide b-amyloide et/ou le peptide b-amyloide

Publications (1)

Publication Number Publication Date
ZA989745B true ZA989745B (en) 1999-05-04

Family

ID=9512632

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA989745A ZA989745B (en) 1997-10-24 1998-10-26 Peptides capable of inhibiting the interaction between the presenilines and the precursor of the beta-amyloid peptide and/or teh beta-amyloid peptide and interaction test for research of mulecules inhibiting the said interaction

Country Status (8)

Country Link
AT (1) ATE521630T1 (pl)
DK (1) DK1025121T3 (pl)
ES (1) ES2372586T3 (pl)
FR (1) FR2770217B1 (pl)
PL (1) PL198079B1 (pl)
PT (1) PT1025121E (pl)
SI (1) SI1025121T1 (pl)
ZA (1) ZA989745B (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6815175B2 (en) 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3510244B2 (ja) * 1991-01-21 2004-03-22 エラン ファーマシューティカルス，インコーポレイテッド アルツハイマー病に関するテストおよびモデル
US5986054A (en) * 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
EP0876483A1 (en) * 1996-01-26 1998-11-11 HSC Research and Development Limited Partnership Nucleic acids and proteins related to alzheimer's disease, and uses therefor

Also Published As

Publication number Publication date
ATE521630T1 (de) 2011-09-15
SI1025121T1 (sl) 2011-12-30
PL198079B1 (pl) 2008-05-30
FR2770217B1 (fr) 2001-12-07
DK1025121T3 (da) 2011-11-28
ES2372586T3 (es) 2012-01-24
PT1025121E (pt) 2011-11-04
FR2770217A1 (fr) 1999-04-30
PL340054A1 (en) 2001-01-15

Similar Documents

Publication Publication Date Title
Wait et al. Strategies for proteomics with incompletely characterized genomes: the proteome of Bos taurus serum
Deibler et al. Chromatographic fractionation of myelin basic protein: Partial characterization and methylarginine contents of the multiple forms
Simon et al. The glutamine residues reactive in transglutaminase-catalyzed cross-linking of involucrin.
McKeehan et al. Purification and partial characterization of the aminoacyl transfer ribonucleic acid binding enzyme from rabbit reticulocytes
Dingwall et al. A polypeptide domain that specifies migration of nucleoplasmin into the nucleus
Laver Structural studies on the protein subunits from three strains of influenza virus
Garrels Changes in protein synthesis during myogenesis in a clonal cell line
Trüeb et al. Type VI collagen is composed of a 200 kd subunit and two 140 kd subunits.
Suchanek et al. Translation of melittin messenger RNA in vitro yields a product terminating with glutaminylglycine rather than with glutaminamide.
Bromer et al. Amino acid sequence of bovine glucagon
Fischer‐Colbrie et al. Isolation and characterization of chromogranins A, B, and C from bovine chromaffin granules and a rat pheochromocytoma
McDonald et al. Mitochondrial proteomics: Undercover in the lipid bilayer
Chang et al. Studies on the status of free amino and carboxyl groups in cobrotoxin
Lundell et al. Isolation and partial characterization of two different subunits from the molybdenum-iron protein of Azotobacter vinelandii nitrogenase.
DE69132814T2 (de) Neues insulinähnliches wachstumsfaktor bindendes protein igfbp-5
Kreil Biosynthesis of Melittin, a Toxic Peptide from Bee Venom: Amino‐Acid Sequence of the Precursor
Champion et al. A two‐dimensional protein map of Chinese hamster ovary cells
CA2273196A1 (en) Isolated mammalian monocyte cell genes; related reagents
Changchien et al. The function of the N-terminal region of ribosomal protein S4
MXPA94006367A (es) Gene novedoso.
Hogue-Angeletti Subunit structure and amino acid composition of xylose isomerase from Streptomyces albus.
Beard et al. Studies on Marsupial Proteins V. Amino Acid Sequence of the?-Chain of Haemoglobin From the Grey Kangaroo, Macropus Giganteus
Walker et al. The Subunits of Rabbit‐Muscle Phosphofructokinase: A Search for Sequence Repetition
Metters et al. Selective cleavage of proenkephalin-derived peptides (less than 23,300 daltons) by plasma kallikrein.
ZA989745B (en) Peptides capable of inhibiting the interaction between the presenilines and the precursor of the beta-amyloid peptide and/or teh beta-amyloid peptide and interaction test for research of mulecules inhibiting the said interaction